BIIB

Biogen Idec Inc. Q1 2007 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2007. Biogen Idec Inc. is an international biotechnology company focused on oncology, neurology, and immunology. The company's primary products include AVONEX, RITUXAN, TYSABRI, FUMADERM, and ZEVALIN. The filing notes the recent acquisition of Syntonix Pharmaceuticals, Inc., and the ongoing commercialization of TYSABRI following its re-launch in the U.S. and Europe.

Key Financial Metrics

Note: Debt figures represent total notes payable (current and non-current). Working capital increased significantly due to the reclassification of tax reserves.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 17.1% to $715.9 million, driven by a 19.1% increase in product revenues and a 12.9% increase in unconsolidated joint business revenues.
• Product Performance:
  • AVONEX: Revenues rose 14.1% to $448.8 million, primarily due to price increases in the U.S. and favorable exchange rates internationally.
  • TYSABRI: Revenues turned positive at $29.8 million (compared to negative $0.2 million in Q1 2006) following the product's re-launch.
  • RITUXAN (Joint Business): Royalty revenue from sales outside the U.S. increased 30.2% to $56.5 million.
• Expense Increases:
  • R&D: Increased 31.2% to $191.4 million, driven by clinical trial costs and a $18.4 million charge for acquired in-process research and development (IPR&D) from the Syntonix acquisition.
  • SG&A: Increased 21.8% to $188.1 million, largely due to sales and marketing activities for TYSABRI.
• Accounting Changes: Adoption of FASB Interpretation No. 48 (FIN 48) resulted in a $14.2 million reduction in unrecognized tax benefits, impacting goodwill and deferred tax liabilities.

Outlook, Risks, and Management Commentary

• Acquisition Impact: The acquisition of Syntonix was accounted for as an asset acquisition, expensing $18.4 million of IPR&D immediately. Future contingent consideration could increase the total purchase price to $124.4 million based on milestones.
• Manufacturing Commitments: The company has committed approximately $274 million to the first phase of its Hillerod, Denmark manufacturing facility and authorized an additional $225 million for the second phase, expected to be ready in 2009.
• Legal Proceedings: Significant litigation includes a class action lawsuit regarding TYSABRI safety disclosures, investigations into RITUXAN promotion practices by the DOJ, and multi-district litigation regarding Medicaid reimbursement pricing. Management states it cannot estimate potential losses at this stage.
• Tax Contingency: The company received a $38.9 million tax assessment from the Massachusetts Department of Revenue for years 2001-2003, which it intends to contest vigorously.
• Guidance: Management anticipates R&D and SG&A expenses will remain higher in 2007 compared to 2006 to support product growth and development.

Key Investor Verification Points

• TYSABRI Market Acceptance: Verify sales velocity and safety data post-re-launch, as future growth is heavily dependent on this product's success.
• Inventory Valuation: Review the $18.1 million value of previously written-down TYSABRI inventory and the impact of recent $6.7 million inventory write-downs on margins.
• Legal Exposure: Monitor the status of the TYSABRI class action, DOJ RITUXAN investigation, and Medicaid pricing litigation for potential material financial impact.
• Manufacturing Capacity: Assess the timeline and cost overruns for the Hillerod facility expansion relative to projected TYSABRI demand.
• Tax Resolution: Track the outcome of the Massachusetts tax assessment and the IRS examination of 2003-2004 returns.